| Investigator, Principal |
NCT04910048: Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA |
|
|
| Active, not recruiting | N/A | 46 | US | POPOP (preoperative patient optimization program), 20Lighter, SOC (standard of care) | University of Arkansas | Osteoarthritis, Knee, Osteoarthritis, Hip, Avascular Necrosis, Rheumatoid Arthritis | 04/23 | 12/24 | | |
NCT06204900: A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery. |
|
|
| Not yet recruiting | N/A | 30 | US | Nerve Cuff and Retractor System | Retropsoas Technologies, LLC | Undergoing a Single-level or Two-level TLIF Surgery | 06/24 | 08/24 | | |
ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator |
|
|
| Recruiting | N/A | 60 | US | Wearable Cardioverter Defibrillator, AUDICOR AM | Zoll Medical Corporation | Heart Failure | 03/24 | 05/24 | | |
| Recruiting | N/A | 60 | US | BHmApp | William Beaumont Hospitals, University of Pennsylvania | Urinary Incontinence | 08/24 | 08/24 | | |
| Recruiting | N/A | 200 | Europe | | Chelsea and Westminster NHS Foundation Trust, ViiV Healthcare | HIV Infections, Gender Identity, Human Immunodeficiency Virus | 04/24 | 10/25 | | |
| Active, not recruiting | N/A | 70 | US | PQ Bypass System | Endologix | Peripheral Artery Diseases | 06/24 | 06/24 | | |
NCT03586414: MitoQ Supplementation and Cardiovascular Function in Healthy Men and Women |
|
|
| Active, not recruiting | N/A | 31 | US | MITOQUINOL MESYLATE then placebo, MitoQ, Mitoquinol methanesulfonate, Placebo, then MITOQUINOL MESYLATE | University of Colorado, Denver, University of Colorado Nutrition Obesity Research Center (NORC) | Diastolic Dysfunction | 07/25 | 08/25 | | |
NCT06361797: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes |
|
|
| Not yet recruiting | N/A | 150 | US | Rotator cuff repair augmented with whole bone marrow, Whole bone marrow, Bone marrow aspirate, Rotator cuff repair augmented with concentrated bone marrow, Bone marrow-derived mesenchymal stem cells, Bone marrow concentrate | Johns Hopkins University, ON Foundation | Rotator Cuff Tears | 07/26 | 12/27 | | |
NCT06340503: Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors |
|
|
| Recruiting | N/A | 20 | US | Research-grade accelerometer, National Comprehensive Cancer Network (NCCN) Education Materials, Garmin Vivofit activity tracker, Exercise Consultation Calls, Interview, Physical Activity Index Assessment (Intervention Arm), Physical Activity Index Assessment (Control Arm), Health Surveys | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Breast Cancer, Colon Cancer | 07/25 | 08/25 | | |
NCT02945085: 3D Team Care for Cognitively Vulnerable Older Adults |
|
|
| Recruiting | N/A | 576 | US | Home Based Care Team, Telephone Based Care Team | UConn Health, Patient-Centered Outcomes Research Institute, University of Connecticut | Dementia, Depression, Delirium | 07/24 | 07/24 | | |
NCT04931251: Addressing Cancer-Related Financial Toxicity in Rural Oncology Care Settings |
|
|
| Recruiting | N/A | 780 | US | Financial Navigation | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Neoplasms, Carcinoma | 07/24 | 07/24 | | |
| Active, not recruiting | N/A | 80 | US | Gaming in a virtual environment | Yale University, National Heart, Lung, and Blood Institute (NHLBI) | Cardiovascular Diseases | 07/25 | 07/25 | | |
NCT04927052: A Study to Evaluate the Safety and Efficacy of Revanesse Shape + With Lidocaine Versus Juvederm Voluma With Lidocaine for the Correction of Age-Related Midface Volume Deficit / Lipoatrophy at 6 and 12 Months Post-treatment |
|
|
| Completed | N/A | 136 | Canada | Revanesse Shape + with Lidocaine, Juvederm Voluma with Lidocaine. | Prollenium Medical Technologies Inc. | Volume Deficit in the Mid-face | 08/23 | 08/23 | | |
| Not yet recruiting | N/A | 16 | US | KeraStat cream, M-PART Assessments via MyCap, Clinical Assessments, Feedback phone interview | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Radiation Dermatitis | 08/26 | 08/26 | | |
| Active, not recruiting | N/A | 5000 | RoW | Edoxaban | Daiichi Sankyo, Inc., Daiichi Sankyo (China) Holdings Co., Ltd. | Non-valvular Atrial Fibrillation | 10/24 | 10/24 | | |
ROCK-RT, NCT05169177: Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy |
|
|
| Recruiting | N/A | 50 | RoW | | University of Sydney, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia, Princess Alexandra Hospital, Brisbane, Australia | Liver Neoplasm | 10/24 | 10/26 | | |
NCT01336790: International Lymphatic Disease and Lymphedema Registry |
|
|
| Recruiting | N/A | 5000 | US | | Stanford University, Lymphatic Education & Research Network | Lymphedema | 12/24 | 12/25 | | |
NCT05531357: Physiologic Mechanisms Underlying Ovarian Follicular Waves During the Menstrual Cycle |
|
|
| Completed | N/A | 50 | Canada | Transvaginal ultrasound scans, Finger-prick blood sampling for dried blood spots, Urine sampling, Venipunctures | University of Saskatchewan, Ansh Labs | Reproductive Issues | 03/24 | 03/24 | | |
| Recruiting | N/A | 200 | US | Education and counseling, Education | Georgetown University | Breast Cancer | 12/24 | 12/25 | | |
NCT05689190: Non-invasive Flow Measurements in Patients With Lower Extremity Arterial Disease (LEAD) |
|
|
| Recruiting | N/A | 30 | Europe | | Philips Clinical & Medical Affairs Global, Leiden University Medical Center | Lower Extremity Arterial Disease | 12/24 | 12/24 | | |
NCT05862467: A Pilot Participatory Program Evaluation of a Virtual Trauma Support Program for Autistic Adults |
|
|
| Recruiting | N/A | 30 | US | Written Exposure Therapy (WET) via telehealth | University of Wyoming | Autism, Trauma, Posttraumatic Stress Disorder, Posttraumatic Stress Symptom | 05/25 | 05/25 | | |
NCT04635111: A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment |
|
|
| Recruiting | N/A | 30 | US | TURALIO™ | Daiichi Sankyo, Inc. | Hepatotoxicity, Tenosynovial Giant Cell Tumor | 06/25 | 03/36 | | |
| Recruiting | N/A | 198 | US | Dietary Intervention Classes | University of South Carolina | Diabetes Mellitus, Type 2, Obesity | 12/25 | 03/26 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06054412: An Adjunctive Neurofeedback Training Program to Enhance Wellness Among Trauma-Exposed Postpartum Mothers |
|
|
| Recruiting | N/A | 20 | US | Neuroptimal (Zengar, Inc.) Neurofeedback | Wayne State University | Well-Being, Psychological, Dissociation, Maternal Care Patterns, Maternal Behavior, Maternal Distress, Mood Disturbance, Emotional Regulation, Post Traumatic Stress Disorder | 09/25 | 03/26 | | |
| Active, not recruiting | N/A | 7 | US | Actual device PFO closure, GORE® CARDIOFORM Septal Occluder, Thienopyridine (clopidogrel or prasugrel), Plavix, Effient, Sham device PFO closure | W.L.Gore & Associates | Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale | 12/25 | 08/26 | | |
SILVERCARE_AF, NCT05804747: A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation |
|
|
| Recruiting | N/A | 1100 | RoW | Edoxaban | Daiichi Sankyo, Daiichi Sankyo Korea Co., Ltd. | Atrial Fibrillation | 12/25 | 12/25 | | |
LEARN, NCT05184790: Learning Environment for Artificial Intelligence in Radiotherapy New Technology |
|
|
| Not yet recruiting | N/A | 300 | RoW | | University of Sydney, Princess Alexandra Hospital, Brisbane, Australia, Calvary Mater Newcastle, Australia, Western Sydney Local Health District, Austin Health, Peter MacCallum Cancer Centre, Australia | Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer, Kidney Cancer, Head and Neck Cancer, Liver Cancer, Pancreatic Cancer, Spinal Neoplasm | 01/26 | 01/26 | | |
NCT05022862: Economic Incentives and vDOT for Latent Tuberculosis Infection |
|
|
| Recruiting | N/A | 399 | US | Usual Care, Video Directly Observed Therapy alone, Video Directly Observed Therapy plus Financial Incentives | Johns Hopkins University, National Institute of Allergy and Infectious Diseases (NIAID) | Latent Tuberculosis | 04/26 | 10/26 | | |
NCT05993234: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY) |
|
|
| Recruiting | N/A | 257 | Europe | Trastuzumab deruxtecan, T-DXd, ENHERTU® | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma | 12/26 | 09/27 | | |
| Recruiting | N/A | 1350 | Europe | Trastuzumab deruxtecan, T-DXd | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer | 06/27 | 09/28 | | |
NCT05636397: Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC |
|
|
| Recruiting | N/A | 60 | Canada | L-Citrulline | The Hospital for Sick Children | BPD - Bronchopulmonary Dysplasia, Pulmonary Hypertension, NEC | 12/27 | 03/28 | | |
NCT05181163: Biofilm Formation and Antibiotic Sensitivity Patterns |
|
|
| Not yet recruiting | N/A | 100 | NA | swab | Sohag University | Orthopedic Surgery | 07/22 | 01/23 | | |
| Misselwitz, Benjamin |
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
| Recruiting | N/A | 200 | Europe | | Benjamin Misselwitz | Healthy | 07/25 | 07/25 | | |
| Recruiting | N/A | 20 | Europe | Diet modification | Insel Gruppe AG, University Hospital Bern | Diet, Healthy | 03/24 | 03/24 | | |
BeBiCo, NCT04447742: Bern Birth Cohort / Trajectory of Microbiota Maturation in Healthy Bern Infants - a Network Approach |
|
|
| Recruiting | N/A | 250 | Europe | | University Hospital Inselspital, Berne, University of Bern | Maturation of the Healthy Infant Intestinal Microbiota, Microbial Colonization, Nutrition Disorder, Infant, Milk Expression, Breast, Mental Health Disorder | 03/24 | 03/35 | | |
NCT05800704: Support of Colonization Resistance of the Gut Microbiota With the Synbiotic Food Supplement Nagasin® |
|
|
| Recruiting | N/A | 147 | Europe | Nagasin, maltodextrin | University of Zurich, Insel Gruppe AG, University Hospital Bern, Stadtspital Zürich, Kantonsspital Winterthur KSW, Luzerner Kantonsspital, Cantonal Hosptal, Baselland | C. Difficile Enteritis | 06/24 | 12/24 | | |
NCT04978077: Networks of Bacterium-Metabolite Interactions in the Small Intestine |
|
|
| Recruiting | N/A | 270 | Europe | Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®) | Insel Gruppe AG, University Hospital Bern | Diet, Healthy, Microbial Colonization | 07/24 | 07/24 | | |
COMMIT, NCT05702879: Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success |
|
|
| Recruiting | N/A | 240 | Europe | Ozanimod, TNF Inhibitor, infliximab, adalimumab, etanercept, golimumab, and certolizumab., Steroids, Prednisolon, Vedolizumab, Ustekinumab | Insel Gruppe AG, University Hospital Bern, Bristol-Myers Squibb | Ulcerative Colitis | 01/25 | 01/25 | | |
NCT04482452: Percentage Visualized Mucosa as a Marker for the Quality of Colonoscopy |
|
|
| Recruiting | N/A | 500 | Europe | Colonoscopy | University Hospital Inselspital, Berne | Colonoscopy | 05/22 | 05/22 | | |
| Koo, Ja S |
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
| Ebenbichler, Christoph |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Recruiting | 3 | 2620 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 04/25 | 12/25 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
| Krznaric, Zeljko |
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA) |
|
|
| Completed | N/A | 120 | Europe, RoW | | Takeda | Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative | 03/24 | 03/24 | | |
| Koch, Robert |
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 160 | Europe, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis, Ulcerative Colitis Chronic | 12/24 | 03/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Cao, Qian |
| Active, not recruiting | 3 | 1281 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828, Placebo | Eli Lilly and Company | Ulcerative Colitis | 01/21 | 05/24 | | |
|
|
|
|
| Active, not recruiting | 3 | 1177 | Europe, Canada, Japan, US, RoW | Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC | Eli Lilly and Company | Ulcerative Colitis | 11/21 | 12/24 | | |
|
|
NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 12/24 | 02/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 06/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
|
|
| Recruiting | 3 | 402 | RoW | Vedolizumab IV, Placebo | Takeda | Moderately to Severely Active Ulcerative Colitis | 05/28 | 07/28 | | |
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 2 | 268 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo | Takeda | Crohn's Disease | 09/26 | 07/27 | | |
| saikali, souhail |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Gavarone, Donna M |
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 780 | Europe, Canada, US, RoW | Tirzepatide, LY3298176, Antihyperglycemic medication | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 11/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Recruiting | 3 | 480 | US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Diabetes Type 2 | 06/26 | 07/26 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Recruiting | 3 | 2620 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 04/25 | 12/25 | | |
| zhang, hairong |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 01/25 | 12/26 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
| Kaser, Susanne |
| Recruiting | 4 | 192 | Europe | Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Jardiance(R), Ozempic(R), Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Jardiance(R), Placebo matching empagliflozin and placebo pen injector matching semaglutide, Control / Placebo | The Deutsche Diabetes Forschungsgesellschaft e.V., Boehringer Ingelheim, German Center for Diabetes Research, Federal Ministry of Health, Germany, Ministry of Innovation, Science and Research in North Rhine-Westphalia, Novo Nordisk A/S | Type 2 Diabetes, Non-alcoholic Steatohepatitis (NASH), Non-alcoholic Fatty Liver Disease (NAFLD) | 01/25 | 12/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Recruiting | 3 | 2620 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 04/25 | 12/25 | | |
